Capsugel adds new commercial-scale spray-dried dispersion capacity at Bend Research

Completes first part of planned US$20m expansion at the plant in Oregon, US

Capsugel has installed a commercial-scale spray dryer at the R&D facility of recently acquired Bend Research, which is now part of the company's Dosage Form Solutions (DFS) business.

The new, high-capacity pharmaceutical spray dryer (PSD) can be used for scale-up, quality-by-design studies (QbD), and the production of appropriate toxicology study supplies in a non-GMP environment, and completes the first part of Capsugel's US$20m expansion at the site in Oregon, US.

The installation coincides with ongoing construction to expand spray dried dispersion capacity at Capsugel's cGMP commercial facility, which is set to be completed by June 2015. This includes an additional commercial-scale spray dryer for production of late-stage clinical, launch and commercial spray-dried products.

'The installation further strengthens our comprehensive strategy to provide early- through late-stage product development and commercial spray-dried dispersion manufacturing in one location,' said Jim Nightingale, Managing Director of Bend Research.

'When combined with Bend Research’s science-based formulation development, applied mathematics and modelling, and advanced process development toolkit, we are creating a unique and holistic offering for the development, scale-up, and manufacture of spray-dried products.'

Capsugel says several pharmaceutical companies are already working with Bend Research to prepare for the launch.

Companies